High-grade gliomas produce a metabolic byproduct called guanidinoacetate that accumulates up to 100-fold in tumour tissue compared to healthy brains, according to a study published in Cell. Researchers found that this metabolite drives tumour growth by stimulating surrounding neurons through gamma-aminobutyric acid A receptors, opening a potential new pathway for cancer neuroscience research.
Metabolic Signature of High-Grade Glioma
High-grade gliomas remain aggressive brain tumours with severely limited treatment options for patients. According to multi-omics analyses of 91 primary human brain tissue samples conducted by researchers, these aggressive cancers possess a distinct metabolic signature. The study examined HGGs, lower-grade gliomas, brain metastases, and non-malignant tissue to uncover how tumour metabolism influences disease progression.
The data revealed that guanidinoacetate, an intermediate molecule in creatine synthesis, accumulated approximately 100-fold in high-grade glioma tissue relative to non-malignant brain tissue. Interestingly, creatine and creatinine levels dropped within the tumour samples. This proved that the massive accumulation of guanidinoacetate did not simply stem from standard creatine production processes.
Did you know? Glioma cells actively secrete guanidinoacetate into their local microenvironment rather than converting it into creatine, driven by an imbalance between the creatine synthesis enzymes AGAT and GAMT.
Tumours Exploit Neuronal Signalling Networks
Growing evidence suggests that interactions between gliomas and surrounding neurons actively fuel tumour progression and invasion. Building on this knowledge, researchers noted that guanidinoacetate also accumulates in GAMT deficiency, which is a rare inherited metabolic disorder known to cause seizures. This clinical link prompted the team to test whether glioma-derived guanidinoacetate affects neuronal activity.
Experiments showed that guanidinoacetate directly activates GABA-A receptors. While this receptor signalling normally inhibits mature neurons, neurons residing near gliomas feature altered chloride regulation. This physiological shift alters how the neurons respond to GABA-A activation.
In tumour-infiltrated mouse brain tissue, guanidinoacetate successfully increased neuronal firing rates. Researchers observed zero impact on neuronal firing in the opposite, tumour-free hemisphere of the brain, confirming that gliomas exploit altered local physiology to turn inhibitory signals into excitatory growth stimuli.
Exploring Guanidinoacetate as a Therapeutic Target
To test whether disrupting this pathway could alter disease outcomes, researchers genetically removed AGAT—the specific enzyme responsible for guanidinoacetate synthesis—from glioblastoma cells. Lab cultures showed that removing the enzyme reduced guanidinoacetate production without directly inhibiting isolated tumour-cell growth on its own.
The in vivo results told a different story. Mice implanted with AGAT-deficient glioblastoma cells survived longer than control mice receiving guanidinoacetate-producing tumours. Furthermore, depleting guanidinoacetate suppressed neuronal activity around the tumours and weakened overall tumour-neuron interactions.
Additional experiments demonstrated that guanidinoacetate boosted glioma-cell proliferation by approximately 50% when the tumour cells grew alongside neurons. When cultured alone without neurons, the metabolite had no effect, underscoring the critical role of tumour neuroscience in driving cancer proliferation.
Pro Tip: Future investigations must establish whether safely blocking guanidinoacetate synthesis pathways can translate into effective treatments for human high-grade glioma patients, bridging basic metabolism with clinical neuro-oncology.
Frequently Asked Questions
What is guanidinoacetate (GAA)?
Guanidinoacetate is an intermediate metabolic product in the synthesis of creatine. In high-grade gliomas, it accumulates up to 100-fold compared to non-malignant brain tissue.
How does GAA promote tumour growth?
GAA secreted by glioma cells stimulates surrounding neurons via GABA-A receptors. Because tumour-infiltrated neurons have altered chloride regulation, this interaction increases neuronal firing, which in turn stimulates glioma proliferation.
Can blocking GAA cure glioblastoma?
Genetically removing the GAA-synthesizing enzyme AGAT increased survival times in mice and reduced tumour-neuron interactions, but further research is required to determine safety and efficacy in humans.
Join the Conversation
What are your thoughts on the intersection of cancer metabolism and neuroscience? Share your perspective in the comments below, or subscribe to our newsletter for the latest updates in oncology research.
Keep reading